NSCLC atlas · 1,053 patients · public data

Which lung cancers over-express your drug target?

TCGA tumour RNA for 16 ADC, bispecific and checkpoint targets, compared with adjacent normal lung: adenocarcinoma vs squamous.
Who the patients are: surgically removed, untreated tumours; 962 of the 996 patients with a known stage are stage I–III. A reference for target biology, not a metastatic or treated population. 1,053 patients (566 LUAD, 487 LUSC); 994 have tumour RNA (LUAD 510, LUSC 484). Every % in the table is of these.
Public data: TCGA open access (cBioPortal PanCancer Atlas 2018, GDC) · built 2026-11-12
Ask Orain's AI about your target →Compare your cohort with these 1,053 patientsOrain runs the same tables on your own cohort: bring slides or data, and its AI analyst answers in your project. Free to start. Pricing

Share of tumours with the target's RNA above normal lung, by type

How to read: bars = RNA in these TCGA tumours, compared with normal lung (above normal = more than 2 standard deviations over the normal-lung average). Protein column = IHC rates from published studies: to size a patient group, use the protein column.

TargetAdenocarcinoma (LUAD), n = 510Squamous (LUSC), n = 484Published IHC (other patients)
TROP2 TACSTD225%46%High IHC: 64% adeno, 75% squamous
B7-H3 CD27632%52%Protein in 80% of NSCLC
HER3 ERBB347%2%Any HER3 IHC: 98.5%, advanced NSCLC
c-MET MET36%12%c-MET high (FDA label cut): 13.5%, non-squamous
HER2 ERBB253%7%HER2 3+: 1.9% of NSCLC
CEACAM551%22%High: 22% adeno, 2.8% squamous
EGFR13%44%High EGFR IHC: 31%, advanced NSCLC
PD-L1 CD274Low RNA in both types (6% · 7% above normal)PD-L1 ≥50%: 22%; ≥1%: 52%
Nectin-4 NECTIN484%92%Any IHC 55%; moderate-strong 27%

Three questions this data answers

Who the patients are

Patients
1,053
Median age
67
Male
59.8%
Median TMB
7.3
Median overall survival
50.2 months

Data in this atlas · All

Patients
1.1KPatients396Deaths recorded8.9KClinical values
Patients with a value
Tumour mutation burden1.1KSex1KStage996Genome altered987Progression-free survival987Disease-specific survival986Overall survival986Aneuploidy983Age971
Driver mutations
1.1KPatients sequenced2.1KDriver alterations22Genes, variants and fusions
Patients with the alteration
TP53699KRAS175KMT2D152KEAP1151NF1122CDKN2A98NFE2L290EGFR84PIK3CA81STK1180KRAS G12C70ARID1A67Other309
RNA
994Patients profiled38.8KValues33Genes6Signatures
Patients profiled
LUAD510LUSC484
Protein (RPPA)
677Patients profiled44.3KValues67Proteins
Patients profiled
LUAD360LUSC317
H&E slides
1.1KDiagnostic slides956Patients824 GBImage data
Slides
LUAD541LUSC512

Overall survival

0%25%50%75%100%024487296120monthsLUADLUSC
LUAD · 505 patients, 182 deathsLUSC · 481 patients, 206 deaths

Driver mutations · All

TP5366.4%KRAS16.6%KMT2D14.4%KEAP114.3%NF111.6%CDKN2A9.3%NFE2L28.5%EGFR8%PIK3CA7.7%STK117.6%KRAS_G12C6.6%ARID1A6.4%

Stage · All

Stage I514Stage II282Stage III166Stage IV34Unknown57

What a sample can be compared on

  • Clinical + survival · 16 values
  • Driver mutations · 22 values
  • RNA · 39 values
  • Protein (RPPA) · 67 values